Table 1.
Demographic characteristics of lung cancer patients in the H group and non-H group before and after matching.
Table 2.
Comparison of indicators of the quality of EOL care in lung cancer patients in the H and non-H groups in the last month of life before and after matching.
Fig 1.
Abbreviations: ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification; CIC, catastrophic illness certificate.
Fig 2.
Kaplan-Meier estimates of survival curves for patients with advanced lung cancer stratified into the non-H and H groups.
Fig 3.
Box plots of costs in the last month of life for patients with advanced lung cancer in the non-H and H groups before and after 2:1 propensity score-matching.
The mean values of costs in the last month of life in the non-H and H groups were US $1,821 (median = 910, SD = 2,441) and US $1,839 (median = 1,600, SD = 1,638) before 2:1 propensity-score-matching and US $2,024 (median = 1,236, SD = 2,498) and US $1,838 (median = 1,590, SD = 1,649) after 2:1 propensity-score-matching, respectively.
Fig 4.
Area under the receiver operating characteristic curve (AUC) was 0.786 for the prediction of high cost (above US $4,721) among patients with advanced lung cancer in their last month of life.
Table 3.
Multivariate Cox proportional hazards model of the factors associated with high health care costs in the last month of life before and after matching.